A Morphological and Immunohistochemical Study of the Tumoral and Inflammatory Cells in Pancreatic Ductal Adenocarcinoma

This study is aimed at investigating tumoral and inflammatory cells and the significance of the prognostic factors of pancreatic ductal adenocarcinoma (PDAC); it is also aimed at determining the role of immunohistochemistry in the diagnosis and prognosis of this neoplasm. Materials and Methods. 230...

Full description

Saved in:
Bibliographic Details
Published in:Journal of immunology research 2020-09, Vol.2020 (2020), p.1-8
Main Authors: Stroescu, Cezar, Dumitrascu, Traian, Brasoveanu, Vladislav, Ghinescu, Minerva, Popescu, Irinel, Vasilescu, Catalin, Dima, Simona Olimpia, Sajin, Maria, Cretoiu, Dragos, Pechianu, Nicolae Catalin, Iorgescu, Andreea Cristina, Mustafa, Elena Stoica, Herlea, Vlad, Ungureanu, Constantin
Format: Article
Language:English
Subjects:
Adenocarcinoma
Cancer
Cloning
Coagulation factors
Cyclin-dependent kinase inhibitor p21
Differential diagnosis
Immunohistochemistry
Immunology
Inflammation
Lymphatic system
Matrilysin
Medical prognosis
Metastases
Morphology
Neoplasia
p53 Protein
Pancreas
Pancreatic cancer
Patients
Prognosis
Statistical analysis
Surgery
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study is aimed at investigating tumoral and inflammatory cells and the significance of the prognostic factors of pancreatic ductal adenocarcinoma (PDAC); it is also aimed at determining the role of immunohistochemistry in the diagnosis and prognosis of this neoplasm. Materials and Methods. 230 cases of pancreatic ductal adenocarcinoma were included in the study group; these cases were selected from the archives of the Department of Pathology of the Fundeni Clinical Institute over a ten-year period. Immunohistochemistry was performed using the following antibodies: MUC 1, CD 34, Factor VIII, CD 68, MMP-7, CEA, p21, p53, and Ki 67. Results. There were 133 male (57.8%) and 97 female (42.2%) patients included in this study, with ages between 20 and 81 years old (mean age: 58.2 years) and with tumors located in the pancreatic head (n=196; 85.2%), pancreatic body (n=12; 5.2%), and pancreatic tail (n=20, 8.7%), as well as panpancreatic tumors (n=2; 0.9%). Patients presented with early stages (IA and IB), with low pathologic grade (G1), with small size tumors (less than 1-1.5 cm), with tumors located in the head of the pancreas, (p53: negative; p21: positive; and CD 68: positive in peritumoral tissue), with low nuclear index (Ki 67
ISSN:2314-8861
2314-7156
DOI:10.1155/2020/6148286